BRIEF-Momenta and CSL announce deal
January 05, 2017 at 16:12 PM EST
* Momenta and CSL announce collaboration and license agreement to develop fc multimer programs, including m230, a selective immunomodulator of fc receptors
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.